Reduction of platelet adhesion rate

Reduction of platelet adhesion rate" refers to decreasing the ability of platelets to adhere to damaged vascular endothelium or biomaterial surfaces, a process pivotal to thrombosis and hemostasis. This physiological outcome is regulated by several platelet adhesion receptors including glycoprotein Ib-IX-V complex (binds von Willebrand factor), glycoprotein VI and integrins (such as αIIbβ3). Therapeutic modulation of platelet adhesion is central to the prevention of thrombotic events, with various antiplatelet drugs acting to inhibit different components of the adhesion and aggregation pathway. The term itself is not a single molecular entity or receptor but denotes a clinical or experimental endpoint; relevant molecular targets must be specified for a structured molecular target database.

Other names

Decrease in platelet adhesionInhibition of platelet adhesionReduced platelet adhesion rate

Inhibition of adhesive receptor-ligand interaction (e.g., GPIbα-VWF, αIIbβ3-fibrinogen); Blockade of signaling pathways leading to platelet activation; Modification of platelet membrane or surface properties